Products
Sirtratumab Biosimilar Antibody-Drug Conjugate (SLITRK6) for Research
Pre-Made Sirtratumab biosimilar, Whole mAb ADC, Anti-SLITRK6 Antibody: Anti-DFNMYP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sirtratumab vedotin is an antibody drug conjugate (ADC) that delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-524-1mg | 1mg | 4635 |
| GMP-Bios-ab-524-10mg | 10mg | |
| GMP-Bios-ab-524-100mg | 100mg | |
| GMP-Bios-ab-524-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sirtratumab biosimilar, Whole mAb ADC, Anti-SLITRK6 Antibody: Anti-DFNMYP therapeutic antibody |
| INN Name | Sirtratumab |
| Target | SLITRK6 |
| Format | Whole mAb ADC |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Astellas/Agensys;Seattle Genetics |
| Conditions Approved | na |
| Conditions Active | Bladder Cancer |
| Conditions Discontinued | na |
| Development Tech | na |
About target - SLITRK6
1. Protein SLIT and NTRK-like protein 6
2. Gene SLITRK6
3. Organism Homo sapiens (Human)
Function
Regulator of neurite outgrowth required for normal hearing and vision.
